Investors currently view BGI Genomics as an underperforming ...
Investors currently view BGI Genomics as an underperforming company, largely influenced by its poor revenue growth over the past years. Its P/S ratio may tumble further if the company fails to improve its revenue growth, leading to further investor disappointment.
Improved Revenues Required Before BGI Genomics Co., Ltd. (SZSE:300676) Shares Find Their Feet
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment